Login to Your Account

Other News To Note

Tuesday, October 16, 2012

• Nektar Therapeutics Inc., of San Francisco, said preclinical data were reported at the Society for Neuroscience meeting in New Orleans for NKTR-171, a sodium channel blocker to treat neuropathic pain.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription